Nice reminder Dungiven. It does make me wonder too what the...

First 3625 Last

Share
Profile

Follow
Torpy

1,555 Posts.

618

15/03/23

10:32

Post #: 66772763
Share

Originally posted by Dungiven: ↑

Which should reassuringly address @strangelogic 's concerns about "competing claims down the track" because ultimately we have supply from Bene for a range of indications.

The original supply agreement info from the $PAR prospectus provided for exclusive supply within specific territories, and specific fields. These fields, at the very beginning, included "Bone Marrow Edema, Asthma, Rhinitis and Chronic Obstructive Pulmonary Disease.

Then in the September 2020 ann. regarding the enhancement of the supply agreement (screenshot below) we expanded these even further (it was speculated at the time that the expanded indications meant the inclusion of ARDS and Heart Failure - but we weren't provided specifics).

There are also our patents, of course. In fact it could be riskier for Arthropharm to try to cross these lines than almost anyone else, because the supply of their own API from Bene for veterinary product could be put at risk. It did definitely make me wonder what the game was though, when I saw their name attached to the MDPI release.

Expand

Nice reminder Dungiven.
It does make me wonder too what the angle is with this work as PAR are potentially the biggest beneficiary of the review (independent summary of PPS validating many of its mechanisms and highlighting the potential depth of the pipeline, a great read for a potential partner!).
These statements at the bottom appear to distance Arthropharm from the work itself.

Funding
This study was funded by The Melrose Personal Research Fund, Sydney, Australia.
Acknowledgments
J.M. has received consultancy fees from Arthropharm Pharmaceuticals Pty Ltd. M.M.S. is a clinical research director at Arthropharm Pharmaceuticals Pty Ltd. That company was not involved in the design and interpretation of this review or in the decision to publish this information.

Last edited by Torpy: 15/03/23

PAR Price at posting: $1.39 Sentiment: None Disclosure: Held
5 Upvote

0 Great analysis

Reply